British Journal of Haematology, 2022 a peptide a key regulator of iron in an hepcidin levels can restricted erythro-poiesis and anaemia. myeloproliferative neoplasm (MPN) in we in 99 patients 49 and (SMF) Twenty- four of these patients ruxolitinib a JAK1/2 inhibitor for treatment of MF.
A. Zhou +9 more
semanticscholar +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
JEADV Clinical Practice, EarlyView.ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
Analysis of MicroRNA -155-5p Expression in Patients with Primary Myelofibrosis.
مجلة كلية الطبBackground: Primary myelofibrosis is a chronic myeloproliferative neoplasm characterized by abnormal megakaryocyte proliferation and fibrosis that destroys healthy bone marrow.
Sarah I. Khaleel +1 more
doaj +1 more source
Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms [PDF]
, 2010 A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm.
Chim, CS, Fung, TK, Wan, TS, Wong, KF
core +1 more source
Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management
American journal of hematology/oncology, 2018 Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional disease features include bone marrow ...
A. Tefferi
semanticscholar +1 more source
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
British Journal of Haematology, EarlyView.Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan +2 more
wiley +1 more source
Improvement in Primary Autoimmune Myelofibrosis Following a Short Course of Steroids and Intravenous Immunoglobulins [PDF]
, 2022 Swathi Prakash +4 more
openalex +1 more source
Artificial intelligence for risk assessment and outcome prediction in malignant haematology
British Journal of Haematology, EarlyView.Machine learning models allow for dynamic and scalable risk stratification and outcome prediction. Different modalities of data such as electronic health records, patient genetics or laboratory results can be used as input. ML models autonomously select features weighing their prognostic value. Methods of model explainability in feature selection allow
Jan‐Niklas Eckardt +3 more
wiley +1 more source
CD133 marks a stem cell population that drives human primary myelofibrosis
Haematologica, 2015 Primary myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, extramedullary hematopoiesis, and transformation to acute myeloid leukemia.
Ioanna Triviai +7 more
doaj +1 more source
Acute massive myelofibrosis with acutelymphoblastic leukemia [PDF]
, 2009 Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Barış Malbora +5 more
core